Jackson Creek Investment Advisors LLC Has $1.80 Million Stock Holdings in Collegium Pharmaceutical, Inc. $COLL

Jackson Creek Investment Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 263.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,846 shares of the specialty pharmaceutical company’s stock after buying an additional 28,170 shares during the period. Jackson Creek Investment Advisors LLC owned approximately 0.12% of Collegium Pharmaceutical worth $1,799,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Versor Investments LP bought a new stake in shares of Collegium Pharmaceutical in the 3rd quarter worth $1,337,000. Ballast Asset Management LP grew its stake in shares of Collegium Pharmaceutical by 31.1% in the 3rd quarter. Ballast Asset Management LP now owns 114,315 shares of the specialty pharmaceutical company’s stock worth $4,000,000 after acquiring an additional 27,109 shares in the last quarter. Wedge Capital Management L L P NC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth $2,697,000. JPMorgan Chase & Co. grew its stake in shares of Collegium Pharmaceutical by 193.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 211,757 shares of the specialty pharmaceutical company’s stock worth $7,409,000 after acquiring an additional 139,689 shares in the last quarter. Finally, Hillsdale Investment Management Inc. grew its stake in shares of Collegium Pharmaceutical by 14.1% in the 3rd quarter. Hillsdale Investment Management Inc. now owns 203,000 shares of the specialty pharmaceutical company’s stock worth $7,103,000 after acquiring an additional 25,100 shares in the last quarter.

Collegium Pharmaceutical Price Performance

COLL opened at $33.78 on Wednesday. The firm has a market cap of $1.10 billion, a P/E ratio of 16.56 and a beta of 0.76. The firm has a 50-day moving average of $34.23 and a 200 day moving average of $41.55. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. Collegium Pharmaceutical, Inc. has a fifty-two week low of $28.74 and a fifty-two week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. The company had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.49 earnings per share. On average, research analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on COLL. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a research note on Tuesday, February 10th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $57.50.

Insider Activity

In related news, EVP Scott Dreyer sold 49,976 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the transaction, the executive vice president owned 71,770 shares in the company, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David Dieter sold 13,976 shares of the stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the transaction, the executive vice president owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. The trade was a 15.35% decrease in their position. The SEC filing for this sale provides additional information. 1.85% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.